Ana de Barros, PhD,  —

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Articles by Ana de Barros

Personalized Speech Tool Gives Individual Voice to Patients with Serious Impairments

VocaliD and Tobii Dynavox recently announced a collaborative agreement to develop a new generation of personalized assistive communication devices (ACDs) for people with serious speech impairments, including some patients with cerebral palsy. The partnership will provide recent and long-term users of Tobii Dynavox devices the option of speaking through their own VocaliD…

First ‘Race for the Dream’ to Support Children with Cerebral Palsy

The  non-profit organization Ireland’s Dream is hosting its first 5k run/walk Sept. 17 at Jack Abernathy Park in Davidson, Mich., to benefit children with cerebral palsy. According to a press release, the event will include the exclusive Cerebral Palsy Swagger – a friendly short race that invites everyone including those  living…

United Cerebral Palsy Invites Teams to Raise Money via STEPtember Exercise Challenge

United Cerebral Palsy (UCP) will participate in STEPtember, an international and monthlong campaign that encourages people to raise money by performing daily exercises equivalent to walking 10,000 steps a day throughout September. The effort supports programs and services that improve the lives of people with disabilities like cerebral palsy (CP). “Cerebral palsy is the most…

FDA Approves Dysport for Lower Limb Spasticity in Pediatric Patients

The U.S. Food and Drug Administration (FDA) approved Ipsen Biopharmaceuticals’ supplemental Biologics License Application for Dysport (abobotulinumtoxinA) injection for the treatment of lower limb spasticity in pediatric patients ages 2 and older. Patients with spasticity have an abnormal increase in muscle tone or stiffness, which may interfere with movement or…